Prilenia
10
2
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
20.0%
2 terminated/withdrawn out of 10 trials
71.4%
-15.1% vs industry average
30%
3 trials in Phase 3/4
140%
7 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Role: lead
Pridopidine Phase 3 Study in Huntington's Disease
Role: lead
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Role: lead
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Role: lead
HEALEY ALS Platform Trial - Regimen D Pridopidine
Role: collaborator
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
Role: lead
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Role: lead
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
Role: lead
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Role: lead
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Role: lead
All 10 trials loaded